Prohost Outperformers Today

From Prohost Elite Group VRTX CLOSED AT $120.34 UP $2.74 2.33% ILMN CLOSED AT $187.17 UP $2.80 1.52% REGN CLOSED...

Prohost Biotech

March 27, 2015

1 min read

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Comments (0)

Please sign in to join the discussion

Today's Highlights

Premium

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Eli Lilly & Centessa Pharmaceuticals Story March 31, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Centessa Pharmaceuticals plc ( CNTA ) announced a definitive agreement for Lilly to acquire...

Prohost Biotech

Mar 31, 2026

Today's Highlights

Premium

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Biogen in the NEWS Today, March 30, 2026, Biogen Inc ( BIIB ) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by th...

Prohost Biotech

Mar 30, 2026

Today's Highlights

Premium

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals in the NEWS March 27, 2026, Rocket Pharmaceuticals ( RCKT ) announced that the U.S. FDA has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel), an autologous...

Prohost Biotech

Mar 27, 2026

Prohost Outperformers Today

Unlock Premium Content

Tags

Comments (0)

Related Articles

Lilly to acquire Centessa Pharmaceuticals to Advance Treatments for Sleep-Wake Disorders

Biogen: FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Rocket Pharmaceuticals Announced FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I